Achillion Is Tripped Up, But The Negativity Is Overdone

On Monday after the close, Achillion Pharmaceuticals revealed that the FDA has placed a partial clinical hold on the development of lead candidate sovaprevir following the discovery of elevated liver enzymes in some patients exposed to a potential combination therapy for patients diagnosed with both HCV and HIV.

http://seekingalpha.com/article/1531622-achillion-is-tripped-up-but-the-negativity-is-overdone?source=feed